HER2 negative

HER2 negative is a term used in breast cancer diagnosis to describe tumors that do not have an excess of the HER2 protein on their surface. HER2, or Human Epidermal growth factor Receptor 2, is a protein that can promote the growth of cancer cells. In some cases, breast cancer cells have an excess of this protein, which can lead to more aggressive and fast-growing tumors. However, in HER2 negative breast cancer, this protein is not present in excess, which can affect the treatment and prognosis of the disease.

Diagnosis

The diagnosis of HER2 negative breast cancer is made through a biopsy of the tumor. The tissue sample is then tested in a laboratory for the presence of the HER2 protein. This is typically done using a test called an immunohistochemistry (IHC) test. If the test shows that the tumor cells do not have an excess of the HER2 protein, the cancer is classified as HER2 negative.

Treatment

The treatment for HER2 negative breast cancer can vary depending on the specific characteristics of the tumor and the overall health of the patient. Treatment options can include surgery, radiation therapy, chemotherapy, and hormone therapy. Because HER2 negative tumors do not respond to drugs that target the HER2 protein, such as Herceptin, other forms of treatment are typically used.

Prognosis

The prognosis for HER2 negative breast cancer can vary widely depending on a number of factors, including the size and stage of the tumor, the patient's overall health, and the specific treatments used. In general, HER2 negative tumors tend to grow more slowly than HER2 positive tumors, but they may be less responsive to certain types of treatment.

See also

• Breast cancer
• HER2 positive
• Immunohistochemistry
• Herceptin

HER2 negative Resources
Latest articles Most recent articles Ongoing trials	Wikipedia